reboxetine

ApprovedSmall molecule

UUniversity of Zurich

reboxetine is one of 116 small molecule programs targeting Adverse Effect. It is currently in Approved.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EffectActive, not recruiting

Major Depressive DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Adverse EffectPreclinical

Active, not recruiting

Major Depressive DisorderApproved

Active, not recruiting

SchizophreniaApproved

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

reboxetine

UUniversity of Zurich

Approved

1 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 6

Zocor

OOrganon and Co

Preclinical

6 7

Depakote

Ibrance

Lunesta

3 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depression1 trial

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

Completed·ZZentrum für Integrative Psychiatrie·N/A·NCT00993876·45 enrolled

Emotional Dysregulation1 trial

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

Recruiting·—·Phase 2·NCT05133804·53 enrolled

Adolescent1 trial

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Unknown status·GGeha Mental Health Center·Phase 4·NCT00426946·60 enrolled

Transcranial Direct Current Stimulation1 trial

Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 4·NCT00853866·12 enrolled

Major Depressive Disorder1 trial

Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00209807·42 enrolled

10 more indications

ISS1 trial

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

Completed·UUniversity of Zurich·N/A·NCT04371146·120 enrolled

Adverse Effect1 trial

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Completed·HHadassah Medical Organization·N/A·NCT00421369·35 enrolled

AIN1 trial

Studying the Role of Brain Molecules for Decision Making

Completed·UUniversity of Zurich·N/A·NCT04384562·160 enrolled

Antidepressants1 trial

Antidepressants and Bone Mineral Density

Completed·GGuiyang Medical University·Phase 3·NCT02179268·203 enrolled

Methamphetamine1 trial

Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT00886886·16 enrolled

Surgery1 trial

Reboxetine for Sleep Apnoea After ENT Surgery

Recruiting·FFlinders University·Phase 2·NCT05978505·20 enrolled

Single Dose1 trial

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

Completed·UUniversity Hospital Bispebjerg and Frederiksberg·Phase 1·NCT04097288·24 enrolled

Humans1 trial

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Completed·UUniversity of Oxford·N/A·NCT03957174·107 enrolled

Schizophrenia1 trial

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Unknown status·FFundació Sant Joan de Déu·Phase 4·NCT01300364·249 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for reboxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — reboxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for reboxetine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Zurich

reboxetine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depression1 trial

Emotional Dysregulation1 trial

Adolescent1 trial

Transcranial Direct Current Stimulation1 trial

Major Depressive Disorder1 trial

ISS1 trial

Adverse Effect1 trial

AIN1 trial

Antidepressants1 trial

Methamphetamine1 trial

Surgery1 trial

Single Dose1 trial

Humans1 trial

Schizophrenia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News